6,989 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Purchased by Man Group plc

Man Group plc purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 6,989 shares of the company's stock, valued at approximately $289,000.

Other hedge funds have also recently bought and sold shares of the company. Jones Financial Companies Lllp grew its position in shares of Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after buying an additional 357 shares in the last quarter. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at about $69,000. AlphaQuest LLC raised its position in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock worth $76,000 after acquiring an additional 1,658 shares in the last quarter. Summit Investment Advisors Inc. increased its stake in Mirum Pharmaceuticals by 8.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock worth $172,000 after purchasing an additional 312 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Mirum Pharmaceuticals by 260.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,112 shares of the company's stock valued at $211,000 after acquiring an additional 3,694 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $73.00 target price on shares of Mirum Pharmaceuticals in a report on Monday, May 19th. Raymond James restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. JMP Securities boosted their price objective on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. Finally, Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals currently has an average rating of "Buy" and an average target price of $60.73.

Mirum Pharmaceuticals Stock Up 0.6%

Shares of MIRM stock traded up $0.27 during trading hours on Thursday, reaching $44.00. The company had a trading volume of 513,504 shares, compared to its average volume of 520,424. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.83 and a 12 month high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The business has a fifty day simple moving average of $42.74 and a 200-day simple moving average of $44.64. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -21.78 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. The business had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Mirum Pharmaceuticals's quarterly revenue was up 61.2% compared to the same quarter last year. During the same period last year, the company posted ($0.54) earnings per share. On average, research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 27,279 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $1,206,004.59. Following the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at $6,129,318.61. The trade was a 16.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Patrick J. Heron bought 1,335 shares of the stock in a transaction on Tuesday, March 4th. The stock was purchased at an average price of $45.57 per share, for a total transaction of $60,835.95. Following the completion of the purchase, the director now owns 163,643 shares of the company's stock, valued at approximately $7,457,211.51. This trade represents a 0.82% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 92,764 shares of company stock worth $4,109,161. 14.36% of the stock is owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.